Non-nucleoside reverse transcriptase inhibitors

A compound represented by formula I:

• 73
• wherein
• R1 is selected from the group consisting of H, halogen, (C1-4)alkyl, O(C1-6)alkyl, and haloalkyl;
• R2 is H or (C1-4)alkyl;
• R3 is H or (C1-4)alkyl;
• R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl;
• and
• Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q is selected from the group consisting of:
• a)
• 74
• wherein one of E and G is C(O) and the other is NR5 wherein R5 is selected from the group consisting of H, hydroxy and (C1-4)alkyl unsubstituted or substituted with pyridinylmethyl, (pyridinyl-N-oxide)methyl or C(O)OR6 wherein R6 is H or (C1-4)alkyl;
• and each R7 is independently H, Me or Et;
• or
• b)
• 75
• wherein E is NR8 wherein R8 is H, (C1-4)alkyl unsubstituted or substituted with C(O)OR9 wherein R9 is H or (C1-4)alkyl;
• or
• c)
• 76
• G wherein D and G are NR10 wherein each R10 is independently H or (C1-4)alkyl unsubstituted or substituted with C(O)OR11 wherein R11 is H or (C1-4)alkyl;
• or
• d)
• 77
• wherein one of L, M, Y and Z is NR12 wherein R12 is H, (C1-4)alkyl unsubstituted or substituted with C(O)OR12x wherein R12x is H or (C1-4)alkyl;
• one of the remaining positions of L, M, Y and Z adjoining the NR12 is C(O);
• and the remaining two positions are each CR13R13 wherein each R13 is independently H, Me or Et;
• or
• e)
• 78
• wherein three adjoining positions of L, M, Y and Z (namely L-M-Y or M-Y-Z) represent NR14—C(O)—O— or —NR15—C(O)—NR16— wherein R14, R15 and R16 each represents H or (C1-4)alkyl unsubstituted or substituted with C(O)OR17 wherein R17 is H or (C1-4)alkyl;
• and the remaining position of L, or Z is CR18R18 wherein each R18 is H, Me or Et;
• or a pharmaceutically acceptable salt, or prodrug thereof.